Next Generation Dx Summit features COVID-19 updates across four conferences: Enabling Point-of-Care Diagnostics, Point-of-Care Technologies, Advanced Diagnostics for Infectious Disease, and Diagnostics Reimbursement. Can't decide on a single program? We encourage program-hopping at the Next Generation Dx Summit to help attendees maximize their on-site experience.


track1-POCT tech

Enabling Point-of-Care Diagnostics

August 25-26, 2020
View Program


Geospatial “Hot Spots” Need Rapid Point-of-Care Diagnostics to Stop Highly Infectious Threats and Antimicrobial Resistance
Gerald Kost, MD, PhD, MS, FAACC, Director, Point-of-Care Testing Center for Teaching and Research (POCT•CTR); Emeritus Professor, School of Medicine, University of California, Davis

Rapid Development of Diagnostic Tests for New Threats: 2019 Novel Coronavirus Pneumonia (COVID-19) and Other Pathogens
Timothy Minogue, Diagnostic Systems Division, United States Army Medical Research Institute of Infectious Diseases

Point-of-Care Molecular Diagnostics for Disease Outbreak Settings: The Path to the Future
Rachel Spurbeck, PhD, Principal Research Scientist, Health Outcomes and Biotechnology Solutions, Battelle Memorial Institute

Point-of-Care Technologies

August 26-27, 2020
View Program


The Next Generation of Continuous Diagnostic Sensors: A Case Study on the Breakthroughs for Sweat Biosensing
Jason Heikenfeld, PhD, Vice President, Operations, Office of Innovation; Professor and Director, Novel Device Laboratory, University of Cincinnati

Global Considerations with Nucleic Acid at POC
Nardev Ramanathan, PhD, Global Lead Analyst, Digital Transformation, Lux Research, Inc.

CASE STUDY: From AIDS to Ebola, Commercializing Rapid Tests for Infectious Disease
Stephen Tang, PhD, President & CEO, OraSure Technologies, Inc.


Advanced Diagnostics for Infectious Disease

August 26-27, 2020
View Program

Presentations by:

DOD’s Pursuit of Pre-Symptomatic Non-Invasive Diagnostics
Edward Argenta, Science & Technology Manager, Biological & Chemical Technologies, Defense Threat Reduction Agency

The Biofire Pneumonia Panel: Does It Relate to Microbiological and Clinical Variables?
Kenneth Rand, MD, Medical Director, Clinical Microbiology Laboratory; Professor, Pathology and Medicine, University of Florida

Clinical Metagenomic Sequencing and Human Host Response: Changing the Diagnostic Paradigm?
Charles Chiu, MD, PhD, Professor, Laboratory Medicine and Medicine/Infectious Diseases, Director, UCSF-Abbott Viral Diagnostics and Discovery Center, Associate Director, UCSF Clinical Microbiology Laboratory, UCSF School of Medicine


Coverage and Reimbursement for Advanced Diagnostics

August 25-26, 2020
View Program


Coding for The Frontlines: Establishing CPT® Codes for Novel Coronavirus (SARS-CoV-2) Tests
Zach Hochstetler, Director, CPT Editorial and Regulatory Services, American Medical Association, AMA

PANEL DISCUSSION: Hot Button Issues in Dx Reimbursement

Danielle Scelfo, Senior Director, Health Policy and Reimbursement, Hologic, Inc.
Ester Stein, MBA, Director, Corporate Reimbursement, Government Affairs, Abbott Laboratories

Jim Almas, MD, Vice President and National Medical Director, Clinical Effectiveness, LabCorp
Marc Hartstein, Principal, Health Policy Alternatives
Julie Khani, President, American Clinical Laboratory Association


Register by July 24 & SAVE $200! 

Premier Sponsors

Corporate Sponsors

View All Sponsors